Surrogate endpoints, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease by Rosendaal, F.R.
Reprinted from JAMA <B The Journal of the American Medical Association August 25, 1999 Volume 282 Copyright 1999, American Medical Association
COINTROVERSIES
Surrogate End Points, Health Outcomes, and
the Drug-Approval Process for the Treatment
of Risk Factors for Cardiovascular Disease
ßrueeM.Psaty, MD, PhD
Nool S. Weiss, MD, DrPH
Curt D. Furberg·, MD, PhD
Thoraas D. Kocpscll, MD, MPH
David S. Siscovick, MD, MPH
Frits R. Roscndaal, MD, PhD
Nicholas L. Smith, PhD, MPH
Susan R. Hcckbcrt, MD, PhD
Robort C. Kaplan, MS
Danyu Lin, PhD
Thomas R. Fleming, PhD
Edward H. Wagner, MD, MPH
DATA ON SURROGATE END POINTS SUCH AS BLOODpressure or body weight have often been used tosupporl the approval of new pharmacologic treal-ments for cardiovascular risk factors. In small,
short-lerm sludies, a new drug reduces the level of a risk
faclor, and the changes in risk factor levels are iiiterpreted
äs if the health beiiefits expected on the basis of those changes
will necessarily follow. An editorial on the pharmaco-
therapy of obesity illuslrates the argument1: in thc context
of discussing the associatioii between appetite suppressant
drugs and primary pulmonary hypertension,2 the editori-
alists used observational evidence on the associatioii of body
mass index with mortality and translated data on weight loss
in a small, short-term trial of dexfenfluramine3 into an es-
timate of lives lhal could be saved by long-term drug therapy
for obesity. The US Food and Drug Administration (FDA)
approved dexfenfluramine on the basis of this same Surro-
gate end poirit argument4: "the polential health benefits of
anorectic drugs outweigh their risk when considered against
the health hazards of obesity."5 When, after the drug was
approved, the adverse effects werc found to be grealer than
eslimated on the basis of preapproval trials,6'7 the drug was
wilhdrawn. Is this an example of the drug-approval pro-
See also p 790.
cess working well, or does it point to a fundamental flaw in
the way drugs are approved?
Surrogate end points sometimes fail to serve äs valid pre-
dictors of important health outcomes.8 One remedy would be
to require, prior to approving new drug therapies for cardio-
vascular risk factors, large, long-term clinical trials lo assess
the drug's effects on major disease end points. The historical
precedent of having accepted Surrogate endpoints and the cur-
rent interest in minimizing the time to drug approval may make
this approach impracticable. Alternatively, a regulär require-
ment for phase 4 trials would perhaps be a practical and achiev-
able strategy for drug approval, one that improves incremen-
lally upon the current approach, which usually requires no
olher evaluation than the use of Surrogate end points.
Cardiovascular Risk Factors äs Surrogate End Points
Surrogate end poinls traditionally have been used to approve
drug therapies for cardiovascular risk factors—obesity, hy-
pertension, hypercholesterolemia, and diabetes mellitus. An
argument based on Surrogates appears to have the logical ap-
peal and the formal slructure of deduction: a risk faclor causes
morbidity and mortality, and the Intervention reduces the risk
factor level; therefore, the Intervention will reduce the risk of
morbidity and mortalily.9 This rationale represents an argu-
ment by analogy radier than empirical evidence.
Maiiy cardiovascular risk factors presenl äs asymptomatic con-
ditions. With rare exceptions, hypertension and hypercholes-
terolemia do not produce Symptoms before a cardiovascular
event. The Symptoms of type 2 diabetes mellitus are often so
mild that estimating the date of onset is difficult. These risk fac-
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tors are associated with major complications, most commonly
stroke, myocardial infarction, renal failure, and congestive heart
failure Although physicians routmely momtor risk factor lev-
els durmg therapy, the purpose of treatment is lo reduce die
occurrence of ihese often devastatmg complicalions
Drug therapies for ihese risk factois are often long-term,
sometimes lifelong For most patients, the absolute risk of
cardiovascular disease is low For instance, in the Systohc
Hypertension m the Elderly Program,10 the rates for the com-
bmed end pomts of stroke or coronary disease were 271
and l 87 per 100 person-years m the placebo and tieated
groups, respectively The risk difference of 0 84 events means
that m order to prevent l cardiovascular event, about 120
older adults with isolated systohc hypertension need to be
treated for l year Most treated patients will receive httle
benefit If there are unanticipated adverse effects, even rela-
tively uncommon ones may mmimize or ehmmate the av-
erage health benefits expected from drug therapy
Surrogate end pomts have several potential advantages
Climcal tnals evaluatmg Surrogate end pomts require smallcr
sample sizes, and they can sometimes be completed m weeks
or months rather than years If the end pomt is hpid levels,
tnals of hpid-lowermg therapy typically mclude around 100
patients observed for 3 to 12 months If the end pomt is the
mcidence of cardiovascular events, the tnals often require
several thousand patients observed for 4 to 5 years l l l 2 The
ability to bring potentially effective therapies to clmical prac-
tice quickly and mexpensively makes Surrogate end pomls
attractive in the drug-approval process
The prmcipal disadvantage of usmg Surrogates lo assess
therapies is the possibihty of an mcomplete, madequate, or
misleadmg evaluation 8 i314 To use only a Surrogate end pomt
is to accept äs empincal evidence for clmical practice a hy-
pothesis about health benefits that has never been tested
Drug therapies usually have multiple effects, and resortmg
to a smgle Surrogate end pomt that focuses exclusively on
l mlermediate effect often precludes the evaluation of other
intended or umntended health effects While even large clmi-
cal tnals may not be able to provide a complete evaluation
of safety for rare adverse events, the small sample sizes and
short trial durations typically required in Surrogate end pomt
trials provide httle assurance of long-term safety
Clinical Trials of Drug Therapies
for Cardiovascular Risk Factors
The results of long-term trials of hpid level reduction have
been mixed In men wilh hypercholesterolemia, clofibrate
was associated with a 20% decrease m the risk of ischemic
heart disease but a 44% mcrease m the iisk of total mortal-
ity 15 le> In a meta-analysis of cholesterol reduclion tnals,17
the fibrates were associated with a 30% mcrease m the risk
of noncoronary disease mortahty (95% confidence mterval
[CI], 8%-56%) and a 19% mcrease m total mortahty (95%
CI, 3%-33%) In part äs a result of the adverse effects seen
with clofibrate, the FDA encouraged the pharmaceutical m-
dustry to mount long-term trials and evaluate 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) leductase m-
hibitors in terms of major disease end pomts The large trials
evaluatmg simvastatm and pravastatm have recently clem-
onstrated important reductions m the occurrence of car-
diovascular events m patients with and wilhout pieexist-
mg coionary disease " l 2 1 8 Thus, some importanl health
outcomes of cholesterol-lowermg trials appear to depend
on the class of drug used to lower cholesteiol level
Similarly, evidence from large trials of hypertension treal-
ments suggests that the fmdmgs for the Surrogate end pomt
of blood pressure reduction may fall to miiror those for the
end pomt of mcidence of coronary disease In a meta-analysis,19
low-dose dmretic therapy was associated with a reduced risk
of coronary heart disease (relative risk reduction [RRR], 28%,
95% CI, 15%-39%), but not for high-dose dmretic therapy
(RRR, 1%, 95% CI, -18% to 17%) or ß-blockcr therapy (RRR,
7%, 95% CI, -9% to 20%) While all 3 regimens loweied blood
pressure, drug trealment with high-dose dmretic therapy 01
ß-blocker therapy failecl to prevent coronary heart disease
Some of the possible explanations for the lack of benefit of
high-dose diuretics have been reviewed20 The health outcomes
of blood pressure reduction appear to depend not only on the
type but perhaps also on the dose of the drug
The largest US trial demonstratmg the health effects of treat-
mg type 2 diabetes melhtus is still the Umversity Gioup Dia-
betes Program 21 In this placebo-controlled mal, tolbuta-
mide was associated with a doubhng of the risk of
cardiovascular mortahty (relative risk [RR], 2 61,95% CI, l 29-
5 27) In contrast to the fmclmgs for type l diabetes melli-
tus,22 intensive treatment of type 2 diabetes melhtus, com-
pared with usual care, has yieldcd equivocal results While
intensive treatment was associated with delayecl onset of micro-
vascular disease m one trial,23 the fmdmgs of another mal24
suggested that persons who receive intensive treatment foi
type 2 diabetes melhtus may have a higher cardiovascular mor-
talily rate than those who receive usual care (RR, l 67, 95%
CI, 0 88-3 13) In a recent UK mal of patients with type 2
diabetes, intensive blood glucose contiol with insulm or sul-
fonylureas was associated with a decreased risk of miciovas-
cular but not macrovascular complications 25 However, the
Interpretation of this large, complex trial is difhcult26
The effects of drug therapies on levels of glucose and gly-
cosylated hemoglobin or even their effects on the occurrence
and progression of microvascular disease may not predict their
overall health effects on macrovascular disease 27 In patients
with type 2 diabetes melhtus, macrovascular disease is twice
äs common äs microvascular disease, and fatal macrovascu-
lar disease is 70 times more common than fatal microvascu-
lar disease 28 New therapies are available or expected soon, m-
cluchng troghtazone and Inhibitors of gluconeogenesis 01
hpolysis 29 Approval of these therapies by the FDA depends
on the ability of the drugs to reduce levels of blood glucose
or glycosylated hemoglobin m small, short-term trials even
though these drugs are likely to be used by milhons of clia-
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beüc patients for extended periods. The liver damage associ-
ated with iroglitazone is an examplc of the postapproval dis-
covery of major toxicily thal led to Lhe drug's being withdrawn
in the United Kingdom30 and perhaps dampened enthusiasm
for the therapy in the United States.31
Validating a Surrogate äs a Risk Factor vs Using a
Surrogate to Evaluate a New Therapy
The literature on Surrogate end points often has failed to dis-
tinguish between the effort to validate a Surrogate end poiiit
äs a risk factor and the use of a Surrogate end point to evalu-
ate a new therapy. In the first instancc, the validation of a Sur-
rogate end point is similar to showing that a risk factor is likely
to be the cause of a disease. Strong, consistent, and indepen-
dent demonstrations of the association in observational slud-
ies help to establish the factor äs a "risk factor" for the oul-
come. Randomized triafs showing that some form of treatmenl
reduces both the level of the risk factor and the occurrence
of the outcome of interest provide good evidence for a causal
association. Unfortunately, randomized trials are not tests of
particular risk factors or mechanisms of therapies. They are
always trials of particular interventions, often specific drugs
in particular doses. One trial of a drug from a single class does
not provide much Information about the validity of the Sur-
rogate end point because the evaluated therapy may in fact
work through a mechanism completely independenl of the
Surrogate. In other words, Surrogate end points are best vali-
daled äs "risk factors" by multiple trials using drugs from a
variety of drug classes. With this sort of evidence, wc can be
more confident aboul our conclusion of the Status of the "sur-
rogate end point" äs a "cause" of the disease.
In the second instance, a Surrogate end point is used to
evaluale a new therapy äs safe and effective. This aclivily
involves generalizing from one drug or class of drugs to an-
olher drug or class of drugs. The argument for the ap-
proval of a new drug on the basis of Surrogates takes the
following lorm: (1) in large, long-term clinical trials, drug
A reduces both the Surrogate end point and the disease in-
cidcnce; (2) in short-lerm trials, drug B reduces the levcl of
the Surrogate end point; (3) in clinical practice, drug B will
bchavc likc drug A in its cffect on disease incidence. In this
argument by analogy, the net health cffects of the untested
drug are simply assumed to be the same äs the net heallh
effects of the testcd drug. No empirical evidence exists to
establish that these assumed benefits are not meaningfully
offset by somc combination of the known risks, the dem-
onstrated adverse effects, or the unintended, unrecog-
nized, and undocumented effects of the new drug.
The gcneralizalion from l lested therapy to a new therapy
is most likely to be true whert the 2 drugs are similar. If drugs
A and B are from different drug classes, then their disparate
mechanisms of action or adverse effects make the generali-
zation from drug A's demonstrated benefit to drug B's hy-
pothesized benefit more uncertain and tenuous. In other
words, the use of a Surrogate end point to evaluate a new
therapy is most likely to be valid when the 2 therapies rep-
resenl similar drugs, preferably from the same drug class. Para-
doxically, Surrogates are most likely valid where least needed.
Of course, exceptions to the criteria for validating Surro-
gates or evaluating therapies are possible. For example, the
findings for high-dose and low-dose diurctic therapy on the
outcome of coronary disease were not the same even though
both therapies came from the same drug class.1''
Because several antihypertensive drug classes, including low-
dose diuretics and ß-blockers, have been associated with a
reduced risk of myocardial infarction, heart failure, or stroke,
high blood pressure may be regarded äs a validated risk fac-
tor for cardiovascular disease. The use of high blood pres-
sure äs a Surrogate end point to evaluate a new therapy none-
theless remains problematic, especially for new drugs from
new drug classes. Given the various actions of antihyperten-
sive drugs—diuretics, ß-blockers, calcium channel block-
ers, α-blockers, and angiolensin-converting enzyme inhibi-
tors—the assumption of equal net health effects across the
drug classes seems queslionable. Despite comparablc effects
on blood pressure and other risk factors, for example, long-
acling calcium channel blockers are associated with a higher
risk of cardiovascular events than the angiotensin-
converting enzyme inhibitors in hypertensive patients with
type 2 diabetes mellitus.32"34 Even if all available classes of an-
tihypertensive drugs had been tested and shown to reduce
the incidence of cardiovascular disease in large, long-ierm tri-
als, it remains an open question whether the heallh benefits
associaled with the tested drug classes would necessarily be
generalizable to the health outcomes of the next new class of
drugs that may lower blood pressure in short-term trials.
To focus on the Surrogate end point äs if we could inter-
venc directly on the risk factor per se is to ignore major dif-
ferences among pharmacologic agents. Conceptualizing the
issue in lerms of "the Surrogate end point"—drug effects on
risk factor levels—uiifortunately encourages easy exlrapo-
lation from one drug to another drug even though the mecha-
nisms of action, the adverse effects, and the effects on clini-
cal end points may differ markedly between drugs or drug
classes. For the fibrates, cholesterol lowering appears to be
inadequate to counteract other drug effects that increase mor-
tality.15 " For the statins, the stabilization of plaques,35 the
reduction in isoprenoids,36 and the effects on platelets, co-
agulation, endothelial function, and inflammatory re-
sponses37·38 may be important mechanisms that provide health
benefits independent of their ability to lower cholesterol.
Proposed Revisions to the Drug-Approval Process
Major revisions to the drug-approval process in the United
States have been driven hislorically by drug tragedies. In
1938, the FDA acquired new authority to regulate drug safety
after about 107 children died after consuming a poisonous
ingredient in a sulfonamide elixir.39 In 1962, the thalido-
mide tragedy renewed interest in drug rcgulaüon and led
to the Kefauver-Harris Drug Amendments, which required
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that pharmaceutical comparaes, before marketmg their drugs,
demonstrate not only drug safety but also the effectiveness
for mtended use 39
The 1962 requirement for adequate and well-controlled
studies is currently satisfied by Surrogate end point trials for
drug therapies of cardiovascular risk factors Although Sur-
rogate end pomts are important early m the evaluation of drugs
m development, their use m the drug-approval process for
the treatment of what are generally asymptomatic nsk fac-
tors does notprovide an evaluation of meamngful chmcal ef-
fectiveness and hmits the ability to asscss safety by permit-
ting evaluation of the drug m fewer people exposed for a
shorter time In the late 1990s, millions of Amencans are tak-
mg antihypertensive and antidiabetic therapies that have not
been adequately evaluated m large, long-term chmcal trials
Despite the widespread use of calcium channel blockeis, an-
giotensm-convertmg enzyme Inhibitors, α-blockers, sulfo-
nylureas, metformin, and troglitazone, their optimal role in
the treatmenl of hypertension and type 2 diabetes melhtus
based on chmcal trials remains unclear Frorn the point of
view of pubhc heallh, drugs that may be used for many years
by millions of people should be adequately evaluated 40
As Cahff and Kramer41 point out, 'Large randomized tri-
als assessmg therapies for common chromc diseases such äs
hypertension need to happen sooner rather than later m the
development of new therapies, and diese same types of trials
are needed to identify the older therapies that are truly ben-
eficial They suggest that "physicians and health care provid-
ers take the lead m pomting out the need for adequate outcome
data "41 While this strategy might work well m a few instances
relymg on calls for chmcal trials by chmcians is unhkely to pro-
vide a consistent and systematic approach to the evaluation
of the safety and efficacy of drug therapies, old or new
One systematic approach is a requirement that, prior to
their approval, new drug therapies for cardiovascular risk
faclors should be evaluated in large, long-term chmcal tri-
als to assess their effects on major disease end pomts The
use of Surrogate end pomts is avoicled, and the major health
outcomes are known prior to marketmg Such an appioach
would slow the time to drug approval and may meet with
resistance from pharmaceutical manufacturers
An alternative systematic approach is a requirement for the
regulär use of phase 4 trials m the approval of new drug thera-
pies for cardiovascular risk factors This strategy would rep-
resent an mcremental improvement over the current ap-
proach, which usually requires little evaluation other than
the use of Surrogate end pomts m small, short-term studies
These required phase 4 studies should be large, long-term clmi-
cal trials designed to assess the effects of drug therapies on
major disease end pomts over 3 to 5 years The evaluation of
the HMG-CoA reductase Inhibitors is an excellent model Im-
tially approved on the basis of their ability to lower choles-
terol m small, short-term studies, HMG-CoA reductase m-
hibitors have been associated with major reductions in the
risk of heart disease and stroke in large, long-term tri-
als n l2 li! Unfortunately we lack comparable Information for
most drug theiapies for hypertension, diabetes, and obesity
Even such a simple pioposal äs the regulai requirement
of laige, long-term phase 4 trials raises a number of ques-
tions This appioach imphcitly, though provisionally, ac-
cepts the vahdily of Surrogate end pomls Also, lecruit-
ment of subjects for a mal of an approved drug may be
difficult Does every new drug m a class require l large, long-
term phase 4 tnal for the evaluation of health outcomes7
The time and costs of conductmg health-outcome tnals need
to be balanced agamst the Information they would yield
However, givcn the immense costs of long-term treatment
of a large proportion of the population, it is difficult to jus-
tify cost äs a reason not to conduct large, long-term trials
of drug therapies for cardiovascular nsk factors
While the proposal to adopt phase 3 01 phase 4 tnals of
health outcomes for new therapies of caidiovasculai nsk fac-
tors has drawbacks, the cunent System falls to encourage
the chmcal trials that are most important for chmcal prac-
tice 42 In the late 20th Century, the FDA drug-approval pro-
cess may benefit fiom revisions that reflecl both the ad-
vances and the hmitations of oui cunent understandmg of
drug therapies for cardiovasculai risk factois
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